GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
66.02 USD   -0.47%
08/17Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
BU
08/16Gilead Sciences Says Veklury Demonstrates Continued In Vitro Antiviral Activity Against Omicron
MT
08/16Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences Resubmits Application for HIV Treatment Candidate

06/27/2022 | 04:57pm EDT


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
08/17Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier Un..
BU
08/16Gilead Sciences Says Veklury Demonstrates Continued In Vitro Antiviral Activity Against..
MT
08/16Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobili..
AQ
08/16Everest Medicines Terminates Cancer Drug Licensing Deal with Immunomedics
MT
08/16Gilead to Acquire Remaining Worldwide Rights of Trodelvy
AQ
08/16Gilead Sciences Unit Enters Into Licensing Agreement With Everest Medicines for Trodelv..
MT
08/15Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
BU
08/15US Stocks Start Week Higher as Tesla Helps Lift Tech Sector
MT
08/15US Stocks Start Week Higher as Tech, Megacap Growth Stocks Gain
MT
08/15Unity Software, Turquoise Hill fall; Gilead, Moderna rise
AQ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 182 M - -
Net income 2022 3 913 M - -
Net Debt 2022 16 314 M - -
P/E ratio 2022 20,8x
Yield 2022 4,42%
Capitalization 82 747 M 82 747 M -
EV / Sales 2022 3,93x
EV / Sales 2023 3,91x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 66,02 $
Average target price 70,57 $
Spread / Average Target 6,88%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-9.08%82 747
VERTEX PHARMACEUTICALS36.26%77 707
REGENERON PHARMACEUTICALS, INC.0.76%69 351
WUXI APPTEC CO., LTD.-22.47%38 993
BIONTECH SE-41.02%38 973
GENMAB A/S0.72%23 679